Influence of Inflammation-Based Prognostic Score on Mortality of Patients Undergoing Chemotherapy for Far Advanced or Recurrent Unresectable Colorectal Cancer
Influence of Inflammation-Based Prognostic Score on Mortality of Patients Undergoing Chemotherapy for Far Advanced or Recurrent Unresectable Colorectal Cancer
复制标题
DOI：
10.1097/sla.0b013e3181b16e24
复制
发表时间：
2009-08-01
影响因子：
9
通讯作者：
Kubota, Keiichi
中科院分区：
文献类型：
--
作者：
Ishizuka, Mitsuru;Nagata, Hitoshi;Kubota, Keiichi
背景资料：最近的研究表明，改良的格拉斯哥预后评分（mGPS）是一种基于炎症的预后评分，仅包括C反应蛋白（CRP）和白蛋白，是预测癌症患者术后结局的有用工具。目的：探讨mGPS对晚期或复发性不可切除结直肠癌（AR-UCRC）化疗患者预后的影响。研究方法：mGPS计算如下：CRP水平升高（>1.0 mg/dL）的患者根据是否存在低白蛋白血症（
Background: Recent studies have revealed that the modified Glasgow Prognostic Score (mGPS), an inflammation-based prognostic score that includes only C-reactive protein (CRP) and albumin, is a useful tool for predicting postoperative outcome in cancer patients. However, few studies have investigated the mGPS in patients undergoing chemotherapy for far-advanced or recurrent unresectable colorectal cancer (AR-UCRC).Objective: To demonstrate the influence of the mGPS for prognostication of patients undergoing chemotherapy for AR-UCRC. Methods: The mGPS was calculated as follows: patients with an elevated level of CRP (>1.0 mg/dL) were allocated a mGPS of 1 or 2 depending on the absence or presence of hypoalbuminemia (